Igraine (AQSE:KING) Scaled Net Operating Assets : (As of . 20)

View and export this data going back to 2008. Start your Free Trial

What is Igraine Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Igraine's operating assets for the quarter that ended in . 20 was £ Mil. Igraine's operating liabilities for the quarter that ended in . 20 was £ Mil. Igraine's Total Assets for the quarter that ended in . 20 was £ Mil. Therefore, Igraine's scaled net operating assets (SNOA) for the quarter that ended in . 20 was .

Igraine Scaled Net Operating Assets Historical Data

The historical data trend for Igraine's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Igraine Scaled Net Operating Assets Chart

Igraine Annual Data

Trend

Scaled Net Operating Assets

Igraine Semi-Annual Data

Scaled Net Operating Assets

Competitive Comparison of Igraine's Scaled Net Operating Assets

For the Biotechnology subindustry, Igraine's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Igraine's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Igraine's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Igraine's Scaled Net Operating Assets falls into.

Save Embed

;

Save Embed

;

Igraine Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Igraine's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in . 20 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: . 20 )
=	(Operating Assets (A: . 20 )	-	Operating Liabilities (A: . 20 ))	/	Total Assets (A: . 20 )
=	(	-	)	/
=

where

	Operating Assets		(A: . 20 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=		-
=

	Operating Liabilities		(A: . 20 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=		-		-
=

Igraine's Scaled Net Operating Assets (SNOA) for the quarter that ended in . 20 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: . 20 )
=	(Operating Assets (Q: . 20 )	-	Operating Liabilities (Q: . 20 ))	/	Total Assets (Q: . 20 )
=	(	-	)	/
=

where

	Operating Assets		(Q: . 20 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=		-
=

	Operating Liabilities		(Q: . 20 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=		-		-
=

Igraine Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Igraine's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Igraine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Igraine PLC (AQSE:KING) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 Primrose Street, 8th Floor, The Broadgate Tower, London, GBR, EC2A 2EW

Website

https://www.igraineplc.com

Igraine PLC is an investment company. Its business investment is to source and develops breakthrough technologies and commercially attractive discoveries in the health, Medtech, Biotech, and life science sectors.